In the DIRECTOR study where first glioblastoma recurrences were treated with different temozolomide dose regimens, PRS ranged between 7.9 months for MGMT-unmethylated and 12.5 months for MGMT-methylated tumors [58]. This evidence concerns the gene MGMT and glioblastoma.